132 related articles for article (PubMed ID: 34843068)
1. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis.
Wu X; Hong J; Zhou J; Sun Y; Li L; Xie W; Piao H; Xu X; Jiang W; Feng B; Chen Y; Xu M; Cheng J; Meng T; Wang B; Chen S; Kong Y; Ou X; You H; Jia J
Hepatol Int; 2021 Dec; 15(6):1318-1327. PubMed ID: 34843068
[TBL] [Abstract][Full Text] [Related]
2. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.
Wu X; Zhou J; Sun Y; Ding H; Chen G; Xie W; Piao H; Xu X; Jiang W; Ma H; Ma A; Chen Y; Xu M; Cheng J; Xu Y; Meng T; Wang B; Chen S; Shi Y; Kong Y; Ou X; You H; Jia J
Hepatol Int; 2021 Feb; 15(1):82-92. PubMed ID: 33460002
[TBL] [Abstract][Full Text] [Related]
3. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
4. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis.
Chen YC; Peng CY; Jeng WJ; Chien RN; Liaw YF
Aliment Pharmacol Ther; 2015 Nov; 42(10):1182-91. PubMed ID: 26381928
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
Lai XJ; Lian JS; Chen JY; Zhang YM; Jia HY; Zheng L; Yang YD
Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):113-118. PubMed ID: 29804377
[No Abstract] [Full Text] [Related]
8. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
Zoutendijk R; Reijnders JG; Zoulim F; Brown A; Mutimer DJ; Deterding K; Hofmann WP; Petersen J; Fasano M; Buti M; Berg T; Hansen BE; Sonneveld MJ; Wedemeyer H; Janssen HL;
Gut; 2013 May; 62(5):760-5. PubMed ID: 22490523
[TBL] [Abstract][Full Text] [Related]
9. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study.
Wu X; Shi Y; Zhou J; Sun Y; Piao H; Jiang W; Ma A; Chen Y; Xu M; Xie W; Cheng J; Xie S; Shang J; Cheng J; Xie Q; Ding H; Zhang X; Bai L; Zhang M; Wang B; Chen S; Ma H; Ou X; Jia J; You H
Expert Opin Biol Ther; 2018 Jul; 18(sup1):61-69. PubMed ID: 30063860
[TBL] [Abstract][Full Text] [Related]
10. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
[TBL] [Abstract][Full Text] [Related]
11. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.
Wu S; Kong Y; Piao H; Jiang W; Xie W; Chen Y; Lu L; Ma A; Xie S; Ding H; Shang J; Zhang X; Feng B; Han T; Xu X; Huo L; Cheng J; Li H; Wu X; Zhou J; Sun Y; Ou X; Zhang H; You H; Jia J
Liver Int; 2018 Jun; 38(6):1045-1054. PubMed ID: 29119705
[TBL] [Abstract][Full Text] [Related]
12. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
Farina E; Loglio A; Tosetti G; Degasperi E; Viganò M; Gentile C; Monico S; Perbellini R; Borghi M; Facchetti F; Uceda Renteria SC; Ceriotti F; Cerini F; Primignani M; Lampertico P
Aliment Pharmacol Ther; 2023 Jun; 57(12):1407-1416. PubMed ID: 36978230
[TBL] [Abstract][Full Text] [Related]
13. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.
Brancaccio G; Fasano M; Grossi A; Santantonio TA; Gaeta GB
Aliment Pharmacol Ther; 2019 Apr; 49(8):1071-1076. PubMed ID: 30793345
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
16. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
Kim HR; Yim HJ; Kang S; Suh SJ; Kim SY; Hyun JJ; Koo JS; Kim JH; Seo YS; Yeon JE; Lee SW; Byun KS; Um SH
Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.
Shim JH; Lee HC; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Feb; 52(2):176-82. PubMed ID: 20006394
[TBL] [Abstract][Full Text] [Related]
19. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
20. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D.
Huang R; Rao H; Shang J; Chen H; Li J; Xie Q; Gao Z; Wang L; Wei J; Jiang J; Sun J; Jiang J; Wei L
Health Qual Life Outcomes; 2018 Jun; 16(1):124. PubMed ID: 29903024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]